Retreatment with alemtuzumab after a first, successful alemtuzumab treatment in B-CLL

被引：0

作者：

Fiegl, Michael ^{[1
]}

Falkner, Florian ^{[1
]}

Falkner, Andreas ^{[1
]}

Zojer, Niklas ^{[2
]}

Fridrik, Michael ^{[3
]}

Hopfinger, Georg ^{[4
]}

Stauder, Reinhard ^{[5
]}

Gunsilius, Ebehard ^{[5
]}

Kantner, Johanna ^{[5
]}

Erdel, Martin ^{[5
]}

Tinhofer, Inge ^{[6
]}

Gastl, Guenther ^{[5
]}

Greil, Richard ^{[6
]}

机构：

[1] Acad Natters Hosp Tyrol, Natters, Austria

[2] Wilhelminenspital Stadt Wien, Vienna, Austria

[3] Gen Hosp Linz, Linz, Austria

[4] Hanuschspital, Vienna, Austria

[5] Med Univ Hosp, Innsbruck, Austria

[6] Med Univ Hosp, Salzburg, Austria

来源：

BLOOD | 2007年 / 110卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4714

引用

页码：252B / 252B

页数：1

共 50 条

[1] A case report of successful alemtuzumab treatment of a B-CLL patient suffering from renal failure
Haslbauer, F.
ANNALS OF HEMATOLOGY, 2009, 88 (04) : 399 - 400
[2] A case report of successful alemtuzumab treatment of a B-CLL patient suffering from renal failure
F. Haslbauer
Annals of Hematology, 2009, 88 : 399 - 400
[3] Immunological effects and safe administration of alemtuzumab (MabCampath™) in advanced B-CLL
Kennedy, B
Hillmen, P
MEDICAL ONCOLOGY, 2002, 19 : S49 - S55
[4] Immunological effects and safe administration of alemtuzumab (MabCampathࡊ) in advanced B-CLL
Kennedy B.
Hillmen P.
Medical Oncology, 2002, 19 (Suppl 2) : S49 - S55
[5] Feasibility of alemtuzumab re-treatment in heavily pretreated refractory B-CLL/SLL.
Thieblemont, C
Bouafia, F
Antal, D
Salles, G
Coiffier, B
BLOOD, 2003, 102 (11) : 360B - 360B
[6] Different in vitro alemtuzumab induced apoptosis on T and B lymphocytes of B-CLL patients
Berretta, S.
Parrinello, N.
Fargione, G.
Tibullo, D.
Stagno, F.
Chiarenza, A.
Palumbo, G. A.
Di Raimondo, F.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 22 - 23
[7] Subcutaneous alemtuzumab in patients with refractory/relapsed B-CLL after a fludarabine-based regimen.
Bezares, R.
Stemmelin, G.
Argentieri, D.
Lanari, E.
Guy-Garay, E.
Campestri, R.
Bartomioli, M.
Garcia, J.
Giralt, S.
Milone, G.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 360S - 360S
[8] In vitro cytotoxicity of alemtuzumab on B-CLL cells: Differential effect on B and T lymphocytes.
Berretta, Salvatore
Chiarenza, Annalisa
Adamo, Luana
Parrinello, Laura
Buglio, Daniela
Stagno, Fabio
Tibullo, Daniele
Conticello, Concetto
Palumbo, Giuseppe A.
Di Raimondo, Francesco
BLOOD, 2006, 108 (11) : 333B - 334B
[9] Reconstitution of the T cell repertoire following treatment with alemtuzumab in patients with B-cell chronic lymphocytic leukemia (B-CLL).
Rezvany, MR
Tehrani, MJ
Karlsson, C
Lundin, J
Rabbani, H
Mellstedt, K
Österborg, A
BLOOD, 2005, 106 (11) : 837A - 837A
[10] EFFICACY OF ALEMTUZUMAB RETREATMENT AFTER 2 INITIAL COURSES
Basil, Sharrack
Barry, Singer
Aaron, Boster
Ann, Bass
Regina, Berkovich
Giancarlo, Comi
Oscar, Fernandez
Jin, Kim Ho
Volker, Limmroth
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2018, 89 (10):

← 1 2 3 4 5 →